<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>27(7)</volume><submitter>Zeng Y</submitter><pubmed_abstract>The resected pⅢA-N2 non-small-cell lung cancer (NSCLC) patients who could benefit from postoperative radiotherapy (PORT) are not well-defined. The study explored the role of PORT on EGFR mutant and wild-type NSCLC patients. We retrospectively searched for resected pIIIA-N2 lung adenocarcinoma patients who underwent EGFR mutation testing. 80 patients with EGFR wild-type and 85 patients with EGFR mutation were included. 62 patients received PORT. In overall population, the median disease-free survival (DFS) was improved in PORT arm compared to non-PORT arm (22.9 vs. 16.1 months; &lt;i>p&lt;/i> = 0.036), along with higher 2-year locoregional recurrence-free survival (LRFS) rate (88.3% vs. 69.3%; &lt;i>p&lt;/i> = 0.004). In EGFR wild-type patients, PORT was associated with a longer median DFS (23.3 vs. 17</pubmed_abstract><journal>iScience</journal><pagination>110219</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11253153</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The efficacy of postoperative radiotherapy in resected pⅢA-N2 EGFR mutant and wild-type lung adenocarcinoma.</pubmed_title><pmcid>PMC11253153</pmcid><pubmed_authors>Zhang YZ</pubmed_authors><pubmed_authors>He FJ</pubmed_authors><pubmed_authors>Peng YR</pubmed_authors><pubmed_authors>Liu JQ</pubmed_authors><pubmed_authors>Qiu ZH</pubmed_authors><pubmed_authors>Pu XX</pubmed_authors><pubmed_authors>Li YL</pubmed_authors><pubmed_authors>Zhu H</pubmed_authors><pubmed_authors>Huang K</pubmed_authors><pubmed_authors>Zeng Y</pubmed_authors><pubmed_authors>Shi SH</pubmed_authors><pubmed_authors>Wu F</pubmed_authors><pubmed_authors>Zou JA</pubmed_authors><pubmed_authors>Deng C</pubmed_authors><pubmed_authors>Liu XL</pubmed_authors><pubmed_authors>Hu CH</pubmed_authors><pubmed_authors>Huang Y</pubmed_authors><pubmed_authors>Liu YF</pubmed_authors><pubmed_authors>Ma F</pubmed_authors></additional><is_claimable>false</is_claimable><name>The efficacy of postoperative radiotherapy in resected pⅢA-N2 EGFR mutant and wild-type lung adenocarcinoma.</name><description>The resected pⅢA-N2 non-small-cell lung cancer (NSCLC) patients who could benefit from postoperative radiotherapy (PORT) are not well-defined. The study explored the role of PORT on EGFR mutant and wild-type NSCLC patients. We retrospectively searched for resected pIIIA-N2 lung adenocarcinoma patients who underwent EGFR mutation testing. 80 patients with EGFR wild-type and 85 patients with EGFR mutation were included. 62 patients received PORT. In overall population, the median disease-free survival (DFS) was improved in PORT arm compared to non-PORT arm (22.9 vs. 16.1 months; &lt;i>p&lt;/i> = 0.036), along with higher 2-year locoregional recurrence-free survival (LRFS) rate (88.3% vs. 69.3%; &lt;i>p&lt;/i> = 0.004). In EGFR wild-type patients, PORT was associated with a longer median DFS (23.3 vs. 17</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jul</publication><modification>2025-04-04T15:02:30.648Z</modification><creation>2025-04-04T15:02:30.648Z</creation></dates><accession>S-EPMC11253153</accession><cross_references><pubmed>39021795</pubmed><doi>10.1016/j.isci.2024.110219</doi></cross_references></HashMap>